ArticleCNS drugs2017
Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.
Article in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Prevalence and Predictors of Substance Use Disorder Due to Gabapentinoids in Patients With Chronic Non-Cancer Pain: A Cross-Sectional Study.Health science reports · 2026Article
- A hospital-based multi-centric observational study to explore the prevalence and correlates of non-medical use and dependence of pregabalin among the patients with substance use disorder in Punjab & Chandigarh.Substance abuse treatment, prevention, and policy · 2026Observational
- Addressing Gabapentinoids' Access Challenges in Saudi Arabia Under New Prescription Regulations: An Expert View.Pain and therapy · 2025Review
- Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.CNS drugs · 2024Article
- Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study.CNS drugs · 2024Article
- Prescribing Patterns and Off-Label Use of Gabapentinoid Agents at Dhulikhel Hospital, Nepal: A Cross-Sectional Study.Journal of pain research · 2024Article
- Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.Pain and therapy · 2020Review
- Current Evidence on Abuse and Misuse of Gabapentinoids.Drug safety · 2020Review
- Spatiotemporal modelling of pregabalin prescribing in England with effect of deprivation.BMJ open · 2020Article
- Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020Review
- Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions.Brain sciences · 2019Article
- Pregabalin: A range of misuse-related unanswered questions.CNS neuroscience & therapeutics · 2019Article
- Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients.Frontiers in psychiatry · 2019Article
- Mirogabalin and emerging therapies for diabetic neuropathy.Journal of pain research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe antiepileptic drug pregabalin is one of the best-selling pharmaceutical products worldwide. There are increasing concerns about its potential for misuse and dependence especially among patients with former or current substance use disorders (SUDs).
objectiveOur objective was to clarify the extent and pattern of pregabalin use as well as motives and predictors in this population.
methodsWe conducted a cross-sectional study with patients on a detoxification ward for illicit drugs at the Center for Psychiatry, Südwürttemberg, Ravensburg in southern Germany from August 2012 until July 2013. We used an extensive questionnaire, part of the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) Axis I Disorders (SCID-I) and urine samples.
resultsOf the 253 participating patients, 56% had used pregabalin at least once. Of these, 92% had acquired it at least in part from illegal sources. The main motives for the use of pregabalin were the attenuation of opioid withdrawal symptoms, the augmentation of other psychotropic substances, and the psychotropic effects of pregabalin itself. Predictors for pregabalin use were opioid and sedative use as well as younger age. The criteria of dependency according to DSM-IV was met by 11% of pregabalin users and 13% of urine samples were positive for pregabalin.
conclusionsUse of pregabalin is common among users of illicit drugs in large parts of southern Germany, with motives for use, acquisition, and mode of use suggesting misuse. The mode of use, especially intake of high doses and concomitant use of other drugs, poses a serious risk to this population, including the development of dependency.
Indexed as
Identifiers
28965335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.